PTGS2 and cancer: Increasing evidence indicates that inflammatory signaling pathways such as the toll-like receptor/myeloid differentiation primary response 88, proinflammatory cytokine, NFκB, and cyclooxygenase-2 pathways are bridging factors between the microbiome and cancer (37).